In the Pipeline

In the Pipeline

Publication
0 followers

Derek Lowe’s long-running independent commentary on drug discovery, clinical development, FDA policy news, and industry trends, hosted at Science/AAAS but written solely by Lowe.

What Success Can Look Like, Darn It
NewsMay 13, 2026

What Success Can Look Like, Darn It

Vepdegestrant, marketed as Veppanu, became the first FDA‑approved bifunctional degrader, a new PROTAC‑type therapy that eliminates target proteins. A Phase III trial showed it works but delivered no clear efficacy advantage over the existing degrader fulvestrant. Pfizer and Arvinas have now...

By In the Pipeline
The Latest News in Vaccine Obstruction
NewsMay 7, 2026

The Latest News in Vaccine Obstruction

Large-scale safety studies of COVID‑19 and shingles vaccines, analyzing millions of records, found rare serious side effects, but the FDA blocked their publication citing unsupported conclusions. The agency also refused to file Moderna’s mRNA flu‑COVID combo vaccine, despite European approval...

By In the Pipeline
Ubiquitin Rides Again
NewsMay 5, 2026

Ubiquitin Rides Again

A new Nature paper introduces a high‑throughput assay that reveals ubiquitination of non‑protein substrates, most notably glycogen. The study shows that ubiquitinated glycogen is routed to lysosomes for degradation, a pathway that intensifies during fasting and is disrupted in glycogen...

By In the Pipeline
Progress Against Pancreatic Cancer, Part One
NewsApr 22, 2026

Progress Against Pancreatic Cancer, Part One

Revolution Medicines reported that its RAS‑targeting small molecule daraxonrasib more than doubled overall survival for patients with metastatic pancreatic ductal adenocarcinoma, extending median survival to 13.2 months versus 6.7 months on standard chemotherapy. The drug works by stabilizing a novel...

By In the Pipeline
Consider the Selfish Ribosome
NewsApr 10, 2026

Consider the Selfish Ribosome

A new preprint argues that ribosomes, not cells, are the primary drivers of life, proposing a ribosome‑centric view of evolution. It suggests early ribosome‑like structures partnered with replicases, later acquiring metabolic functions to sustain themselves. The authors note that no...

By In the Pipeline
New Bond Formations Just Keep On Coming
NewsApr 8, 2026

New Bond Formations Just Keep On Coming

A new Nature paper introduces a streamlined iterative sp³‑sp³ coupling using t‑BuLi‑activated pinacol boronates (B(pin)) and copper(I) catalysis. The protocol retains stereochemistry at the boron‑derived carbon and tolerates a broad range of functional groups, from silyl ethers to pyridines. The...

By In the Pipeline
Right Through the Skull
NewsMar 31, 2026

Right Through the Skull

Researchers have unveiled a novel calvarial delivery platform that injects drug‑laden nanoparticles into the skull’s bone marrow. Immune cells within the diploic space capture the particles and migrate across skull‑meninges channels, ferrying the therapeutic cargo into the brain. In mouse...

By In the Pipeline
In the Pipeline | Pulse